API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/01/2855230/10564/en/Cyclacel-Pharmaceuticals-to-Present-New-Clinical-Data-at-2024-ASCO-Annual-Meeting-Highlighting-Fadraciclib-s-Potential-as-a-Precision-Medicine-for-Cancer.html
https://www.globenewswire.com//news-release/2024/03/07/2842334/10564/en/Cyclacel-Pharmaceuticals-Announces-Preclinical-Proof-of-Concept-Data-for-Fadraciclib-to-be-Presented-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2024.html
https://www.globenewswire.com//news-release/2023/12/18/2797893/10564/en/Cyclacel-Pharmaceuticals-Reports-Fadraciclib-Phase-1-Data-Suggesting-Efficacy-Against-Tumors-With-CDKN2A-CDKN2B-and-MTAP-Deletions.html
https://www.globenewswire.com/news-release/2022/10/13/2533989/10564/en/Cyclacel-Pharmaceuticals-To-Present-Preliminary-Data-From-The-Phase-1-2-Clinical-Trial-Of-Oral-Fadraciclib-At-The-34th-EORTC-NCI-AACR-Symposium.html
https://www.globenewswire.com/news-release/2022/04/12/2420813/10564/en/Cyclacel-Pharmaceuticals-Announces-Publication-Confirming-Fadraciclib-Suppresses-MCL1-and-Synergizes-With-Venetoclax-in-Chronic-Lymphocytic-Leukemia.html
https://www.globenewswire.com/news-release/2021/11/05/2328604/10564/en/Cyclacel-Announces-Dosing-of-First-Patient-in-Phase-1-2-Study-of-Oral-Fadraciclib-in-Patients-With-Leukemias-or-Myelodysplastic-Syndromes.html
https://www.globenewswire.com/news-release/2020/09/21/2096390/0/en/Cyclacel-Announces-Fadraciclib-Abstract-Selected-for-Oral-Presentation-in-the-Late-Breaking-and-Best-Proffered-Paper-Session-at-the-32nd-EORTC-NCI-AACR-Symposium-2020.html